Welcome to our dedicated page for Trevi Therapeutics news (Ticker: TRVI), a resource for investors and traders seeking the latest updates and insights on Trevi Therapeutics stock.
Trevi Therapeutics, Inc. (TRVI) is a clinical-stage biopharmaceutical company advancing Haduvio™, an investigational oral therapy targeting chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC), along with pruritic conditions like prurigo nodularis. This page provides comprehensive access to official company announcements, clinical trial updates, and strategic developments.
Investors and industry professionals will find curated updates on TRVI's research programs, regulatory milestones, and financial performance. Our news collection includes details on Haduvio's dual opioid receptor mechanism, trial design specifics, and collaborative initiatives – all essential for evaluating the company's scientific and commercial trajectory.
Key content categories include clinical trial results, FDA communications, intellectual property updates, executive leadership changes, and financial disclosures. Each update is presented with contextual clarity to serve both expert analysts and those new to biopharma investing.
Bookmark this page for streamlined access to TRVI's evolving story as it progresses through critical development phases. Check regularly for verified updates on therapeutic advancements directly from company filings and authorized communications.
Trevi Therapeutics (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing Haduvio™ for chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC), announced its participation in several investor and medical conferences in September 2024. These include:
- 2024 Wells Fargo Healthcare Conference (Sept 4-6, Boston)
- European Respiratory Society Congress 2024 (Sept 7-11, Vienna)
- H.C. Wainwright 26th Annual Global Investment Conference (Sept 9-11, New York)
- 2024 Cantor Global Healthcare Conference (Sept 17-19, New York)
Senior management, including CEO Jennifer Good and CFO Lisa Delfini, will represent Trevi at these events. Corporate presentations are scheduled at the H.C. Wainwright and Cantor conferences, with the latter being available for public viewing via registration.
Trevi Therapeutics reported its second quarter 2024 financial results and provided business updates. The company is developing the investigational therapy Haduvio™ for chronic cough in IPF and RCC. Key updates include:
1. RIVER Trial: Phase 2a trial in RCC is 80% enrolled with topline data expected in Q4 2024.
2. CORAL Trial: Phase 2b trial in IPF chronic cough with sample size re-estimation milestone in Q4 2024.
3. Financials: Ended the quarter with $69.5 million in cash and expected runway into 2026. R&D expenses increased to $10.0 million, G&A expenses to $3.3 million, leading to a net loss of $12.4 million.
4. Other studies include the HAP study and the TIDAL respiratory physiology study.
Trevi Therapeutics (Nasdaq: TRVI), a clinical-stage biopharmaceutical company, has announced it will report its second quarter 2024 financial results and provide a corporate update on August 8, 2024. The company is developing Haduvio™ (oral nalbuphine ER) for treating chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC). A conference call and live audio webcast will be held at 4:30 p.m. ET on the same day.
Interested parties can join the call by dialing (877) 870 4263 (domestic) or (412) 317 0790 (international) and asking to join the Trevi Therapeutics call. A live audio webcast will be available on the company's website, with an archived replay accessible for 30 days following the event.
Trevi Therapeutics (Nasdaq: TRVI), specializing in therapies for chronic cough, announced their participation in key investor and healthcare events in July and August 2024. Senior management, including CEO Jennifer Good and CFO Lisa Delfini, will represent the company at the Leerink Partners Therapeutics Forum on July 9-10 in Boston, MA. Additionally, two abstracts from Trevi's ongoing clinical trials, CORAL (Phase 2b) and RIVER (Phase 2a), have been accepted for presentation at the 13th London International Cough Symposium on July 18-19, 2024. The symposium will discuss advancements in chronic cough research and treatment. CEO Jennifer Good will also represent Trevi at Oppenheimer's Biotech in the Berkshires on August 5-7 in Lenox, MA, and the Stifel 2024 Biotech Summer Summit on August 12-14 in Newport, RI.
Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company (Nasdaq: TRVI), will participate in upcoming investor, business development, and medical conferences in May and June. The company is focused on developing Haduvio™ for chronic cough in idiopathic pulmonary fibrosis and refractory chronic cough. Senior management will attend various events, including the Citizens JMP Life Sciences Conference, ATS 2024 International Conference, 2024 BIO International Convention, and Oppenheimer's 2024 Montauk Life Sciences Summit.
Trevi Therapeutics, Inc. (Nasdaq: TRVI) reported Q1 2024 financial results and business updates, reaffirming guidance for Phase 2a RIVER trial and HAP Study. Topline data for both trials expected in 2024. IND cleared for Phase 1b trial. Key business updates include progress in clinical trials, with Phase 2a RIVER trial and Phase 2b CORAL trial enrollment ongoing. The company ended Q1 2024 with $72.8 million in cash. Financially, R&D expenses increased to $8.8 million, G&A expenses were $3.1 million, with a net loss of $10.9 million. Conference call/webcast and upcoming meetings announced for investor participation.
Trevi Therapeutics, Inc. (Nasdaq: TRVI) will host a conference call and webcast on May 7, 2024, to discuss the corporate update and financial results for the first quarter of 2024. The company is developing Haduvio™ for chronic cough in IPF and RCC. Investors can participate via phone or webcast.
FAQ
What is the current stock price of Trevi Therapeutics (TRVI)?
What is the market cap of Trevi Therapeutics (TRVI)?
